Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma

Cancer Investigation

Volumn 31, Issue 4, 2013, Pages 241-250

  Pillai, Krishna ^a   Akhter, Javed ^a   Chua, Terence C ^a   Morris, David Lawson ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Biochemical markers; Colorectal and anal cancer; Outcomes research

Indexed keywords

ANTINEOPLASTIC AGENT; BROMELAIN; CISPLATIN; FLUOROURACIL; GLYCOPROTEIN; MUCIN 1; ONCOPROTEIN; RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CELLS; DRUG EFFICACY; DRUG STRUCTURE; GLYCOSYLATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PANCREAS CANCER; PERITONEUM MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; UPREGULATION;

ANIMALS; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BROMELAINS; HUMANS; MESOTHELIOMA; PERITONEAL NEOPLASMS;

EID: 84876923502     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.784777     Document Type: Review

References (144)

1. Leipner J, Saller R. Systemic enzyme therapy in oncology: effect and mode of action. Drugs 2000;59:769-780. (Pubitemid 30232319)
2. Beuth J. Proteolytic enzyme therapy in evidence-based complementary oncology: fact or fiction Integr Cancer Ther 2008;7:311-316.
3. Brien S, Lewith G, Walker AF, Middleton R, Prescott P, Bundy R. Bromelain as an adjunctive treatment for moderate-to-severe osteoarthritis of the knee: a randomized placebo-controlled pilot study. QJM 2006;99:841-850. (Pubitemid 46024095)
4. Klein G, KullichW, Schnitker J, Schwann H. Efficacy and tolerance of an oral enzyme combination in painful osteoarthritis of the hip. A double-blind, randomised study comparing oral enzymes with non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol 2006;24:25-30.
5. Shahid SK, Turakhia NH, Kundra M, Shanbag P, Daftary GV, Schiess W. Efficacy and safety of phlogenzym-a protease formulation, in sepsis in children. J Assoc Physicians India 2002;50:527-531.
6. Maurer HR. Bromelain: biochemistry, pharmacology and medical use. Cell Mol Life Sci 2001;58:1234-1245. (Pubitemid 32850918)
7. Eckert K, Grabowska E, Stange R, Schneider U, Eschmann K, Maurer HR. Effects of oral bromelain administration on the impaired immunocytotoxicity of mononuclear cells from mammary tumor patients. Oncol Rep 1999;6:1191-1199.
8. Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumour growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus). Planta Med 1985;51:538-539. (Pubitemid 16176666)
9. Bhui K, Prasad S, George J, Shukla Y. Bromelain inhibits COX-2 expression by blocking the activation of MAPK regulated NFkappa B against skin tumor-initiation triggering mitochondrial death pathway. Cancer Lett 2009;282:167-176.
10. Bhui K, Tyagi S, Prakash B, Shukla Y. Pineapple bromelain induces autophagy, facilitating apoptotic response in mammary carcinoma cells. Biofactors 2010;36:474-482.
11. Onken JE, Greer PK, Calingaert B, Hale LP. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008;126:345-352.
12. Bhui K, Tyagi S, Srivastava AK, Singh M, Roy P, Singh R, Shukla Y. Bromelain inhibits nuclear factor kappa-B translocation, driving human epidermoid carcinoma A431 andmelanoma A375 cells through G(2)/M arrest to apoptosis. Mol Carcinog 2012;51:231-243.
13. Baez R, Lopes MT, Salas CE, Hernandez M. In vivo antitumoral activity of stem pineapple (Ananas comosus) bromelain. Planta Med 2007;73:1377-1383. (Pubitemid 350084456)
14. Walker AF, Bundy R, Hicks SM, Middleton RW. Bromelain reduces mild acute knee pain and improves well-being in a dose-dependent fashion in an open study of otherwise healthy adults. Phytomedicine 2002;9:681-686. (Pubitemid 36152125)
15. Singer F, Oberleitner H. Drug therapy of activated arthrosis: on the effectiveness of an enzyme mixture versus diclofenac. Wien MedWochenschr 1996;146:55-58.
16. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988;15:1833-1840. (Pubitemid 19037656)
17. Lotti T, Mirone V, Imbimbo C, Corrado F, Corrado G, Garofalo F, Scaricabarozzi I. Controlled clinical studies of nimesulide in the treatment of urogenital inflammation. Drugs 1993;46 (Suppl. 1):144-146. (Pubitemid 23324635)
18. GuoR, Canter PH,Ernst E.Herbalmedicines for the treatment of rhinosinusitis: a systematic review. Otolaryngol Head Neck Surg 2006;135:496-506. (Pubitemid 44441648)
19. Snowden HM, Renfrew MJ, Woolridge MW. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev 2001;CD000046.
20. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7:256-269. (Pubitemid 46486616)
21. Sarkar FH, Adsule S, Li Y, Padhye S. Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy. Mini Rev Med Chem 2007;7:599-608. (Pubitemid 47099180)
22. Mazhar D, Ang R,Waxman J. COX inhibitors and breast cancer. Br J Cancer 2006;94:346-350. (Pubitemid 43237558)
23. Kalra N, Bhui K, Roy P, Srivastava S, George J, Prasad S, Shukla Y Regulation of p53, nuclear factor kappaB and cyclooxygenase-2 expression by bromelain through targeting mitogen-activated protein kinase pathway in mouse skin. Toxicol Appl Pharmacol 2008;226:30-37. (Pubitemid 350235577)
24. Dhandayuthapani S, Perez HD, Paroulek A, Chinnakkannu P, Kandalam U, Jaffe M, Rathinavelu A. Bromelain-induced apoptosis in GI-101A breast cancer cells. J Med Food 2012;15: 344-349.
25. Rowan AD, Buttle DJ. Pineapple cysteine endopeptidases.Methods Enzymol 1994;244:555-568.
26. Hatano K, Kojima M, Tanokura M, Takahashi K. Solution structure of bromelain inhibitor IV from pineapple stem: structural similarity with Bowman-Birk trypsin/chymotrypsin inhibitor from soybean. Biochemistry 1996;35:5379-5384.
27. Hatano K, Sawano Y, Miyakawa T, Tanokura M. Characterization of the acidic and basic limbs of a bell-shaped pH profile in the inhibitory activity of bromelain inhibitor VI. Biopolymers 2006;81:309-319.
28. Hale LP, Greer PK, Trinh CT, James CL. Proteinase activity and stability of natural bromelain preparations. Int Immunopharmacol 2005;5:783-793. (Pubitemid 40248332)
29. Castell JV, Friedrich G, Kuhn CS, Poppe GE. Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol 1997;273:G139-G146.
30. Harrach T, Eckert K, Schulze-Forster K, Nuck R, Grunow D, Maurer HR. Isolation and partial characterization of basic proteinases from stem bromelain. J Protein Chem 1995;14:41-52.
31. Harrach T, Eckert K, Maurer HR, Machleidt I, Machleidt W, Nuck R. Isolation and characterization of two forms of an acidic bromelain stem proteinase. J Protein Chem 1998;17:351-361. (Pubitemid 28242305)
32. Napper AD, Bennett SP, Borowski M, Holdridge MB, Leonard MJ, Rogers EE, Duan Y, Laursen RA, Reinhold B, Shames SL. Purification and characterization of multiple forms of the pineapple-stem-derived cysteine proteinases ananain and comosain. Biochem J 1994;301(Pt 3):727-735. (Pubitemid 24239305)
33. Yoshioka S, Izutsu K, Aso Y, Takeda Y. Inactivation kinetics of enzyme pharmaceuticals in aqueous solution. Pharm Res 1991;8:480-484.
34. Chobotova K, Vernallis AB, Majid FA. Bromelains activity and potential as an anti-cancer agent: Current evidence and perspectives. Cancer Lett 2010;290:148-156.
35. Taussig SJ, Szekerczes J, Batkin S. Inhibition of tumour growth in vitro by bromelain, an extract of the pineapple plant (Ananas comosus). Planta Med 1985;51(6):538-539. (Pubitemid 16176666)
36. Batkin S, Taussig SJ, Szekerezes J. Antimetastatic effect of bromelain with or without its proteolytic and anticoagulant activity. J Cancer Res Clin Oncol 1988;114:507-508.
37. Kleef R, Delohery TM, Bovbjerg DH. Selective modulation of cell adhesion molecules on lymphocytes by bromelain protease Pathobiology 1996;64:339-346. (Pubitemid 27174324)
38. Engwerda CR, Andrew D,MurphyM,Mynott TL. Bromelain activates murine macrophages and natural killer cells in vitro. Cell Immunol 2001;210:5-10. (Pubitemid 32756936)
39. Kelly T. Fibroblast activation protein-alpha and dipeptidyl peptidase IV (CD26): cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resist Updat 2005;8:51-58. (Pubitemid 40797956)
40. Tian Y, Zhang H. Characterization of disease-associated Nlinked glycoproteins. Proteomics 2012.
41. Li QK, Gabrielson E, Zhang H. Application of glycoproteomics for the discovery of biomarkers in lung cancer. Proteomics Clin Appl 2012;6:244-256.
42. Stepien KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ.The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012;64:1011-1019.
43. Rudd PM, Elliott T, Cresswell P, Wilson IA, Dwek RA. Glycosylation and the immune system. Science 2001;291: 2370-2376. (Pubitemid 32231792)
44. Kobata A. Structures and functions of the sugar chains of glycoproteins. Eur J Biochem 1992;209:483-501.
45. Dwek RA. Glycobiology: toward understanding the function of sugars. Chem Rev 1996;96:683-720. (Pubitemid 126649163)
46. Kim YJ, Varki A. Perspectives on the significance of altered glycosylation of glycoproteins in cancer. Glycoconj J 1997;14:569-576. (Pubitemid 27353200)
47. Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002;2:580-592. (Pubitemid 37328733)
48. Semaan SM, Wang X, Marshall AG, Sang QX. Identification of potential glycoprotein biomarkers in estrogen receptor positive (ER+) and negative (ER-) human breast cancer tissues by LCLTQ/FT-ICR mass spectrometry. J Cancer 2012;3:269-284.
49. An HJ, Miyamoto S, Lancaster KS, Kirmiz C, Li B, Lam KS, Leiserowitz GS, Lebrilla CB. Profiling of glycans in serumfor the discovery of potential biomarkers for ovarian cancer. J Proteome Res 2006;5:1626-1635. (Pubitemid 44043097)
50. Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, Ferrige A, Alecio R, Borowsky AD, Sulaimon S, Lebrilla CB, Miyamoto S. A serum glycomics approach to breast cancer biomarkers.Mol Cell Proteomics 2007;6:43-55. (Pubitemid 46152690)
51. Li C, Zolotarevsky E, Thompson I, Anderson MA, Simeone DM, Casper JM, Mullenix MC, Lubman DM. A multiplexed bead assay for profiling glycosylation patterns on serum protein biomarkers of pancreatic cancer. Electrophoresis 2011;32:2028-2035.
52. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, Tennant BC, London WT, Evans AA, Blumberg BS, Dwek RA, Mattu TS, Mehta AS. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005;102:779-784. (Pubitemid 40282742)
53. KufeDW. Targeting the human MUC1 oncoprotein: a tale of two proteins. Cancer BiolTher 2008;7:81-84.
54. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M, Nakayama H.Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 2005;8:86-94. (Pubitemid 40655517)
55. Meert AP, Martin B, Delmotte P, Moriya T, Niikura H, Terada Y, Sato S,Okamura K, Yaegashi N.The role of EGF-R expression on patient survival in lung cancer: a systematic reviewwithmetaanalysis. Eur Respir J 2002;20:975-981. (Pubitemid 35175137)
56. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877-1881. (Pubitemid 38746324)
57. Okamoto S, Ito K, Sasano H, Moriya T, Niikura H, Terada Y, Sato S, OkamuraK, YaegashiN. Ber-EP4 and anti-calretinin antibodies: a useful combination for differential diagnosis of various histological types of ovarian cancer cells and mesothelial cells. Tohoku J Exp Med 2005;206:31-40. (Pubitemid 40568161)
58. Meert AP, Martin B, Paesmans M, Berghmans T, Mascaux C, Verdebout JM,Delmotte P, Lafitte JJ, Sculier JP.Therole of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer 2003;89:959-965. (Pubitemid 37239194)
59. Hale JS, Li M, Sinyuk M, Jahnen-Dechent W, Lathia JD, Silverstein RL. Context dependent role of the CD36-thrombospondin-histidine-rich glycoprotein axis in tumor angiogenesis and growth. PLoS One 2012;7:e40033.
60. Smits G, Campillo M, Govaerts C, Janssens V, Richter C, Vassart G, Pardo L, Costagliola S. Glycoprotein hormone receptors: determinants in leucine-rich repeats responsible for ligand specificity. EMBO J 2003;22:2692-2703. (Pubitemid 36712366)
61. Ryan RJ, Charlesworth MC, McCormick DJ, Milius RP, Keutmann HT. The glycoprotein hormones: recent studies of structure-function relationships. FASEB J 1988;2:2661-2669.
62. Stadlmann J, Pabst M, Kolarich D, Kunert R, Altmann F. Analysis of immunoglobulin glycosylation by LC-ESI-MS of glycopeptides and oligosaccharides. Proteomics 2008;8:2858-2871.
63. Duraisamy S, Kufe T, Ramasamy S, Kufe D. Evolution of the human MUC1 oncoprotein. Int J Oncol 2007;31:671-677.
64. Linden SK, Florin TH, McGuckin MA. Mucin dynamics in intestinal bacterial infection. PLoS One 2008;3:e3952.
65. McAuley JL, Linden SK, Png CW, King RM, Pennington HL, Gendler SJ, Florin TH, Hill GR, Korolik V, McGuckin MA. MUC1 cell surfacemucin is a critical element of themucosal barrier to infection. J Clin Invest 2007;117:2313-2324. (Pubitemid 47219576)
66. Sakamoto H, Yonezawa S,Utsunomiya T, Tanaka S, Kim YS, Sato E. Mucin antigen expression in gastric carcinomas of young and old adults. Hum Pathol 1997;28:1056-1065. (Pubitemid 27388107)
67. Sachdeva M, Mo YY. MicroRNA-145 suppresses cell invasion and metastasis by directly targeting mucin 1. Cancer Res 2010;70:378-387.
68. Raina D, Kharbanda S, Kufe D. The MUC1 oncoprotein activates the anti-apoptotic phosphoinositide 3-kinase/Akt and Bcl-xL pathways in rat 3Y1 fibroblasts. J Biol Chem 2004;279:20607-20612. (Pubitemid 38656454)
69. Yin L, Huang L, Kufe D. MUC1 oncoprotein activates the FOXO3a transcription factor in a survival response to oxidative stress. J Biol Chem 2004;279:45721-45727. (Pubitemid 39491562)
70. Ren J, Agata N, Chen D, Li Y, Yu WH, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents. Cancer Cell 2004;5:163-175. (Pubitemid 38283802)
71. Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO. Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer.Mod Pathol 2005;18:1295-1304. (Pubitemid 41348648)
72. Andren O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, Johansson JE, Mucci LA. MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a populationbased study in Sweden. Br J Cancer 2007;97:730-734. (Pubitemid 47396290)
73. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, Huang L, Kufe DW, Weichselbaum RR. MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 2010;3:16.
74. Budiu RA, Mantia-Smaldone G, Elishaev E, Chu T, Thaller J, McCabe K, Lenzner D, Edwards RP, Vlad AM. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011;60:975-984.
75. Tinder TL, Subramani DB, Basu GD, Bradley JM, Schettini J, Million A, Skaar T, Mukherjee P. MUC1 enhances tumor progression and contributes toward immunosuppression in a mouse model of spontaneous pancreatic adenocarcinoma. J Immunol 2008;181:3116-3125.
76. Roulois D, Blanquart C, Panterne C, Gueugnon F, Gregoire M, Fonteneau JF. Downregulation of MUC1 expression and its recognition by CD8(+) T cells on the surface of malignant pleural mesothelioma cells treated with HDACi. Eur J Immunol 2012;42:783-789.
77. Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW,MillwardMJ. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer 2008;98:1562-1569. (Pubitemid 351652333)
78. Abe M, Kufe D. Structural analysis of the DF3 human breast carcinoma-associated protein. Cancer Res 1989;49:2834-2839. (Pubitemid 19148611)
79. Schroeder JA, Thompson MC, Gardner MM, Gendler SJ. Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland. J Biol Chem 2001;276:13057-13064.
80. Singh PK, Wen Y, Swanson BJ, Shanmugam K, Kazlauskas A, Cerny RL, Gendler SJ, Hollingsworth MA. Platelet-derived growth factor receptor beta-mediated phosphorylation ofMUC1 enhances invasiveness in pancreatic adenocarcinoma cells. Cancer Res 2007;67:5201-5210. (Pubitemid 46997258)
81. Ren J, Raina D, Chen W, Li G,Huang L, KufeD.MUC1 oncoprotein functions in activation of fibroblast growth factor receptor signaling. Mol Cancer Res 2006;4:873-883. (Pubitemid 44877017)
82. Li Y, Yu WH, Ren J, Chen W, Huang L, Kharbanda S, Loda M, Kufe D. Heregulin targets gamma-catenin to the nucleolus by a mechanism dependent on the DF3/MUC1 oncoprotein. Mol Cancer Res 2003;1:765-775. (Pubitemid 37025595)
83. Wang H, Lillehoj EP, Kim KC. Identification of four sites of stimulated tyrosine phosphorylation in the MUC1 cytoplasmic tail. Biochem Biophys Res Commun 2003;310:341-346. (Pubitemid 37163669)
84. Li Y, Kuwahara H, Ren J, Wen G, Kufe D. The c-Src tyrosine kinase regulates signaling of the human DF3/MUC1 carcinomaassociated antigen withGSK3 beta and beta-catenin. J Biol Chem 2001;276:6061-6064.
85. Ren J, Li Y, Kufe D. Protein kinase C delta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling. J Biol Chem 2002;277:17616-17622. (Pubitemid 34967564)
86. Wen Y, Caffrey TC,WheelockMJ, Johnson KR, Hollingsworth MA. Nuclear association of the cytoplasmic tail of MUC1 and beta-catenin. J Biol Chem 2003;278:38029-38039. (Pubitemid 37175334)
87. Hattrup CL, Fernandez-Rodriguez J, Schroeder JA, Hansson GC, Gendler SJ. MUC1 can interact with adenomatous polyposis coli in breast cancer. Biochem Biophys Res Commun 2004;316:364-369. (Pubitemid 38338601)
88. Wei X, Xu H, Kufe D. Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. Cancer Cell 2005;7:167-178. (Pubitemid 40248342)
89. Li Y, Kufe D. The Human DF3/MUC1 carcinoma-associated antigen signals nuclear localization of the catenin p120(ctn). Biochem Biophys Res Commun 2001;281:440-443. (Pubitemid 32928175)
90. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501. (Pubitemid 37328931)
91. Bellacosa A, Chan TO, Ahmed NN, Datta K,MalstromS, Stokoe D,McCormick F, Feng J, Tsichlis P. Akt activationby growthfactors is a multiple-step process: the role of the PH domain. Oncogene 1998;17:313-325. (Pubitemid 28383008)
92. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, Holmes AB, McCormick F, Hawkins PT. Dual role of phosphatidylinositol-3,4,5- trisphosphate in the activation of protein kinase B. Science 1997;277:567-570. (Pubitemid 27369005)
93. Datta SR,DudekH, TaoX,Masters S, FuH, GotohY,Greenberg ME. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-241. (Pubitemid 27456390)
94. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC. Regulation of cell death protease caspase-9 by phosphorylation. Science 1998;282:1318-1321. (Pubitemid 28524494)
95. Kane LP, Shapiro VS, Stokoe D, Weiss A. Induction of NFkappaB by the Akt/PKB kinase. Curr Biol 1999;9:601-604.
96. Zhou BP, Liao Y, Xia W, Zou Y, Spohn B,HungMC.HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001;3:973-982. (Pubitemid 34428742)
97. Lundy J, Thor A, Maenza R, Schlom J, Forouhar F, Testa M, Kufe D. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients. Breast Cancer Res Treat 1985;5:269-276. (Pubitemid 15060454)
98. Zaretsky JZ, Barnea I, Aylon Y, Gorivodsky M, Wreschner DH, Keydar I. MUC1 gene overexpressed in breast cancer: structure and transcriptional activity of the MUC1 promoter and role of estrogen receptor alpha (ERalpha) in regulation of the MUC1 gene expression. Mol Cancer 2006;5:57.
99. Wei X, XuH, Kufe D. MUC1 oncoprotein stabilizes and activates estrogen receptor alpha. Mol Cell 2006;21:295-305. (Pubitemid 43099944)
100. Yin L, Li Y, Ren J, Kuwahara H, Kufe D. Human MUC1 carcinoma antigen regulates intracellular oxidant levels and the apoptotic response to oxidative stress. J Biol Chem 2003;278:35458-35464. (Pubitemid 37102316)
101. Kalra AV, Campbell RB.Mucin impedes cytotoxic effect of 5-FU against growth of human pancreatic cancer cells: overcoming cellular barriers for therapeutic gain. Br J Cancer 2007;97:910-918. (Pubitemid 47519315)
102. Nagata K, Horinouchi M, Saitou M, Higashi M, Nomoto M, Goto M, Yonezawa S. Mucin expression profile in pancreatic cancer and the precursor lesions. J Hepatobiliary Pancreat Surg 2007;14:243-254. (Pubitemid 46863913)
103. Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T, Osako M, Takao S, Batra SK, Aikou T, Imai K, Yonezawa S. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005;58:845-852. (Pubitemid 41113392)
104. Neubauer RA. A plant protease for potentiation of and possible replacement of antibiotics. Exp Med Surg 1961;19:143-160.
105. Garbin F,Harrach T, Eckert K,MaurerH. Bromelain proteinasef9 augments human lymphocyte-mediated growth-inhibition of various tumor-cells in-vitro. Int J Oncol 1994;5:197-203. (Pubitemid 24231845)
106. Tysnes BB,MaurerHR, Porwol T, Probst B, Bjerkvig R,Hoover F. Bromelain reversibly inhibits invasive properties of glioma cells. Neoplasia 2001;3:469-479. (Pubitemid 33151013)
107. Guimaraes-Ferreira CA, Rodrigues EG, Mortara RA, Cabral H, Serrano FA, Ribeiro-dos-Santos R, Travassos LR. Antitumor effects in vitro and in vivo and mechanisms of protection against melanoma B16F10-Nex2 cells by fastuosain, a cysteine proteinase from Bromelia fastuosa. Neoplasia 2007;9:723-733. (Pubitemid 47523234)
108. Mynott TL, Ladhams A, Scarmato P, Engwerda CR. Bromelain, from pineapple stems, proteolytically blocks activation of extracellular regulated kinase-2 in T cells. J Immunol 1999;163:2568-2575. (Pubitemid 29399179)
109. Kalra AV, Campbell RB. Mucin overexpression limits the effectiveness of 5-FU by reducing intracellular drug uptake and antineoplastic drug effects in pancreatic tumours. Eur J Cancer 2009;45:164-173.
110. Gerard G. Anticancer treatment and bromelains. Agressologie 1972;13:261-274.
111. White RR, Crawley FE, Vellini M, Rovati LA. Bioavailability of 125I bromelain after oral administration to rats. Biopharm Drug Dispos 1988;9:397-403.
112. Seifert J, Ganser R, Brendel W. Absorption of a proteolytic enzyme originating from plants out of the gastro-intestinal tract into blood and lymph of rats (authors transl). Z Gastroenterol 1979;17:1-8. (Pubitemid 9084659)
113. Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-168. (Pubitemid 28144151)
114. Hussain SP,Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-2380. (Pubitemid 350022405)
115. Wang MT, Honn KV, Nie D. Cyclooxygenases, prostanoids, and tumor progression. Cancer Metastasis Rev 2007;26:525-534. (Pubitemid 350115125)
116. Hou RC, Chen YS, Huang JR, Jeng KC. Cross-linked bromelain inhibits lipopolysaccharide-induced cytokine production involving cellular signaling suppression in rats. J Agric Food Chem 2006;54:2193-2198.
117. Balkwill F, Charles KA,Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-217. (Pubitemid 40568680)
118. Yoshimura A. Signal transduction of inflammatory cytokines and tumor development. Cancer Sci 2006;97:439-447. (Pubitemid 43811583)
119. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000;12:677-686.
120. Desser L, Rehberger A, Kokron E, Paukovits W. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. Oncology 1993;50:403-407. (Pubitemid 23323706)
121. Desser L, Rehberger A, Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother 1994;9:253-263.
122. Barth H, Guseo A, Klein R. In vitro study on the immunological effect of bromelain and trypsin on mononuclear cells from humans. Eur J Med Res 2005;10:325-331. (Pubitemid 41226978)
123. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008;205: 275-285. (Pubitemid 351281593)
124. Schleicher ED, Bierhaus A, Haring HU, Nawroth PP, Lehmann R. Chemistry and pathobiology of advanced glycation end products. Contrib Nephrol 2001;1-9. (Pubitemid 33816224)
125. Stopper H, Schinzel R, Sebekova K, Heidland A. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 2003;190:151-156. (Pubitemid 36136013)
126. Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008;14:940-945. (Pubitemid 351753280)
127. Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ. CD44 family and gynaecological cancer. In Vivo 2003;17: 633-640. (Pubitemid 38165466)
128. Mayer S, zur Hausen A, Watermann DO, Stamm S, Jager M, Gitsch G, Stickeler E. Increased soluble CD44 concentrations are associated with larger tumor size and lymph node metastasis in breast cancer patients. J Cancer Res Clin Oncol 2008;134:1229-1235.
129. Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260-267.
130. Hale LP, Haynes BF. Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu 8/LAM1 surface molecules and markedly enhances CD2-mediated T cell activation. J Immunol 1992;149:3809-3816. (Pubitemid 23068859)
131. Hale LP, Greer PK, Sempowski GD. Bromelain treatment alters leukocyte expression of cell surface molecules involved in cellular adhesion and activation. Clin Immunol 2002;104:183-190. (Pubitemid 35026228)
132. Secor ER, Jr., Singh A, Guernsey LA, McNamara JT, Zhan L, Maulik N,Thrall RS. Bromelain treatment reduces CD25 expression on activated CD4+ T cells in vitro. Int Immunopharmacol 2009;9:340-346.
133. Fitzhugh DJ, Shan S, Dewhirst MW, Hale LP. Bromelain treatment decreases neutrophil migration to sites of inflammation. Clin Immunol 2008;128:66-74.
134. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006;6:506-520. (Pubitemid 43980540)
135. Desser L, Holomanova D, Zavadova E, Pavelka K, Mohr T, Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-beta levels in human blood. Cancer Chemother Pharmacol 2001;47(Suppl.):S10-S15.
136. Rose B, Herder C, Loffler H, Meierhoff G, Schloot NC, Walz M, Martin S. Dose-dependent induction of IL-6 by plant-derived proteases in vitro. Clin Exp Immunol 2006;143:85-92.
137. Brakebusch M, Wintergerst U, Petropoulou T, Notheis G, Husfeld L, Belohradsky BH, Adam D. Bromelain is an accelerator of phagocytosis, respiratory burst and Killing of Candida albicans by human granulocytes and monocytes. Eur J Med Res 2001;6:193-200.
138. Wu WS, Wu JR, Hu CT. Signal cross talks for sustained MAPK activation and cell migration: the potential role of reactive oxygen species. Cancer Metastasis Rev 2008;27: 303-314.
139. Fialkow L, Wang Y, Downey GP. Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007;42:153-164. (Pubitemid 46001554)
140. Biggerstaff JP,WeidowB,Dexheimer J,Warnes G,Vidosh J, Patel S, Newman M, Patel P. Soluble fibrin inhibits lymphocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis and immunotherapy. Clin Appl Thromb Hemost 2008;14:193-202. (Pubitemid 351364015)
141. Lipinski B, Egyud LG. Resistance of cancer cells to immune recognition and killing. Med Hypotheses 2000;54:456-460. (Pubitemid 30204340)
142. McNicol A, Israels SJ. Beyond hemostasis: the role of platelets in inflammation, malignancy and infection. CardiovascHematol Disord Drug Targets 2008;8:99-117.
143. Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer 2008;123:983-990.
144. Crew KD, Neugut AI. Aspirin and NSAIDs: effects in breast and ovarian cancers. Curr Opin Obstet Gynecol 2006;18:71-75.